SymBiosis
Venture capitalBentonville · Seed–Late Stage · 4 people tracked
Also known as SYMBIOSIS CAPITAL PARTNERS, LLC
Find your way into SymBiosis
536 people in our graph share verified history with the SymBiosis team — schools, employers, funds. One of them is your warm intro.
Investment thesis
SymBiosis invests in biotherapeutic companies across multiple stages, with emphasis on programs in or approaching clinical trials, across various disease indications. The firm operates globally through dedicated funds designed to support long-term investments.
Source: firm website, verified Aug 25, 2026.
Team · 4 people
from public directories
What they invest in
from 6 of 6 portfolio companiesBiotech ×6Healthtech ×4Deep Tech ×3Medical Devices ×2Digital Health ×1Longevity ×1
HQs:United States×4
Investments · 6 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12023 · 12020 · 14 dated
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)Eran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)
Board seatChidozie Ugwumba· per SEC Form D · $70.4M raise · filed Jan 2021
Co-investorsAju IB Invesment CorporationAnzu PartnersGrazia Equity GmbHHealthCapMRL Ventures FundSolasta Ventures+1 more
Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.
BiotechDeep TechHealthtechLongevity
Nils Regge(Co-Founder & General Partner)in
Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalTruVenturo GmbHCTI Life Sciences Fund L.P.+3 more
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)Paula Soteropoulos(Director)Stephen Knight(Director)
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+7 more
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture CapitalSR One Capital ManagementWindham Capital Partners+1 more
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupYsios CapitalAlexandriaFidelity Investments+7 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound enhancing agents) to deliver genetic payloads to targeted sites in a redosable manner.
BiotechDeep TechDigital Health
Kenneth Greenberg(Founder)in
Co-investorsARCH Venture PartnersLeaps by BayerUCB VenturesVida VenturesVivo Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
SonoThera · fiercebiotech.com · Aug 12, 2026
Ensoma · fiercebiotech.com · Aug 7, 2026
Fore Biotherapeutics · technical.ly · Aug 6, 2026
Apollo Health Ventures · cen.acs.org · Apr 16, 2026
Carisma Therapeutics · bizjournals.com · Dec 16, 2025
Frequently asked questions
- What stage does SymBiosis invest at?
- SymBiosis invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does SymBiosis focus on?
- SymBiosis focuses on Biotech.
- Where is SymBiosis located?
- SymBiosis is headquartered in Bentonville, US.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.